EUVIMEDEUVIMED entdecken
Crossref

Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming

He Yang, Haoyu Zhang, Ziyin Zhao, Yuxuan Ren, Yanhan Xu, Kaimin Cai, Jianjun Cheng iD, Xun Liu, Yongbing Chen, Lichen Yin iD

Journal of the American Chemical Society · 11.11.2026 · 148 (44) · 48152-48167

DOI: 10.1021/jacs.6c14840 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the American Chemical Society, online erschienen am 02.11.2026. Verfasst von He Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou215004, China. Hauptthemen laut MEDLINE: Gene Editing, Succinic Acid, Histocompatibility Antigens Class I. Die Arbeit nennt 56 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Collaborative Innovation Center of Suzhou Nano Science and Technology, Higher Education Discipline Innovation Project.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Impaired expression of major histocompatibility complex class I (MHC-I) greatly compromises cytotoxic T-cell-mediated anticancer immunotherapy. Existing MHC-I activation strategies are greatly challenged by poor tumor specificity and off-target toxicity. Herein, we report a dual tumor-specific CRISPR/Cas9 gene editing system that can precisely knock out succinate dehydrogenase subunit C (Sdhc) to activate the MHC-I pathway via epigenetic and transcriptional regulation. A tumor-specific gene editor is first engineered via reversible shielding of sgRNA using an apurinic/apyrimidinic endonuclease 1 (APE1)-responsive, complementary ssDNA, yielding AP-sgRNA with blocked editing activity in normal cells yet completely restored activity in APE1-overexpressing tumor cells. Subsequently, tumor-targeted delivery of AP-sgRNA and Cas9 mRNA (mCas9) is achieved using dibenzocyclooctyne-decorated lipid nanoparticle (DLNP), which upon bioorthogonal click reaction can anchor cancer cells that are prelabeled with azido groups using the unnatural sugar DCL-AAM. Thus, AP-sgSdhc/mCas9@DLNP enables efficient and selective Sdhc editing in tumor cells, leading to epigenetic and transcriptional activation of MHC-antigen processing and presentation genes and thereby provoking robust antitumor efficacy in the B16-OVA melanoma model through enhanced, T cell-mediated immune responses. Moreover, it completely suppressed pulmonary metastasis after combination with aPD-L1 in the 4T1 lung metastasis model. This study provides an enlightened paradigm for precision gene editing and renders a promising mechanism for potentiating cancer immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Gene EditingSuccinic AcidHistocompatibility Antigens Class IAnimalsMiceHumansCRISPR-Cas SystemsCell Line, Tumor

Substanzen

Succinic AcidHistocompatibility Antigens Class I

Autor:innen und Institutionen

  • Department of Thoracic Surgery, The Second Affiliated Hospital of Soochow University, Suzhou215004, China.
  • Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory of Advanced Healthcare Materials and Devices, Soochow University, Suzhou215123, China.
  • Surio Therapeutics Co., LTD., Hangzhou310024, China.
  • School of Engineering, Westlake University, Hangzhou310024, China.

ORCID-Profile: Jianjun Cheng, Lichen Yin

Förderung

  • National Natural Science Foundation of China
  • Collaborative Innovation Center of Suzhou Nano Science and Technology
  • Higher Education Discipline Innovation Project
  • Joint International Research Laboratory of Carbon-Based Functional Materials and Devices

Zitieren

APA

Yang, H., Zhang, H., Zhao, Z., Ren, Y., Xu, Y., Cai, K., Cheng, J., Liu, X., Chen, Y., & Yin, L. (2026). Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming. Journal of the American Chemical Society, 148(44), 48152-48167. https://doi.org/10.1021/jacs.6c14840

Vancouver

Yang H, Zhang H, Zhao Z, Ren Y, Xu Y, Cai K, et al. Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming. Journal of the American Chemical Society. 2026;148(44):48152-48167. doi:10.1021/jacs.6c14840

BibTeX
@article{Yang2026,
  author = {Yang, He and Zhang, Haoyu and Zhao, Ziyin and Ren, Yuxuan and Xu, Yanhan and Cai, Kaimin and Cheng, Jianjun and Liu, Xun and Chen, Yongbing and Yin, Lichen},
  title = {Tumor-Specific Gene Editing Enhances Cancer Immunogenicity through Succinate Metabolism-Mediated MHC-I Reprogramming},
  journal = {Journal of the American Chemical Society},
  year = {2026},
  volume = {148},
  number = {44},
  pages = {48152--48167},
  doi = {10.1021/jacs.6c14840}
}
Kostenlos starten →